MA29882B1 - Antagonistes du recepteur 1 du facteur de necrose des tumeurs servant a traiter des maladies respiratoires - Google Patents

Antagonistes du recepteur 1 du facteur de necrose des tumeurs servant a traiter des maladies respiratoires

Info

Publication number
MA29882B1
MA29882B1 MA30867A MA30867A MA29882B1 MA 29882 B1 MA29882 B1 MA 29882B1 MA 30867 A MA30867 A MA 30867A MA 30867 A MA30867 A MA 30867A MA 29882 B1 MA29882 B1 MA 29882B1
Authority
MA
Morocco
Prior art keywords
lung tissue
formulation
treatment
prevention
manufacture
Prior art date
Application number
MA30867A
Other languages
English (en)
Inventor
Wildt Rudolf M T De
Steve Holmes
Ian M Tomlinson
Gregory P Winter
Mary F Fitzgerald
Justian Craig Fox
Armin Sepp
Jennifer Lee
Benjamin P Woolven
Original Assignee
Domantis Ltd
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd, Argenta Discovery Ltd filed Critical Domantis Ltd
Publication of MA29882B1 publication Critical patent/MA29882B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne l'utilisation d'un agent (tel qu'un fragment d'anticorps, un antagoniste, un ligand, un monomère dAb) qui se lie à une cible dans le tissu pulmonaire pour la fabrication d'une formulation à action prolongée ou à intervalle thérapeutique prolongé destinée à être administrée localement dans le tissu pulmonaire et concerne également des méthodes d'administration à un sujet d'un agent se liant à une cible dans le tissu pulmonaire pour produire un intervalle thérapeutique prolongé dans le tissu pulmonaire. La formulation est destinée à être administrée localement dans le tissu pulmonaire et le procédé consiste à administrer localement ladite formulation dans le tissu pulmonaire. Cette invention concerne également l'utilisation d'antagonistes du récepteur TNF1 pour la fabrication d'une formulation ou d'un médicament servant au traitement, à la prévention ou à la suppression d'une inflammation pulmonaire ou d'une maladie respiratoire et des méthodes de traitement de telles maladies. Cette invention concerne en outre l'utilisation d'agents pour la fabrication d'un dispositif d'administration (tel qu'un inhalateur ou un dispositif d'administration intranasale) en vue du traitement ou de la prévention de l'inflammation pulmonaire ou d'une maladie respiratoire et un dispos d'administration servant au traitement ou à la prévention de l'inflammation pulmonaire ou d'une maladie respiratoire et contenant un agent tel que décrit plus haut.
MA30867A 2005-10-24 2008-04-23 Antagonistes du recepteur 1 du facteur de necrose des tumeurs servant a traiter des maladies respiratoires MA29882B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0521621.3A GB0521621D0 (en) 2005-10-24 2005-10-24 Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases

Publications (1)

Publication Number Publication Date
MA29882B1 true MA29882B1 (fr) 2008-10-03

Family

ID=35458579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30867A MA29882B1 (fr) 2005-10-24 2008-04-23 Antagonistes du recepteur 1 du facteur de necrose des tumeurs servant a traiter des maladies respiratoires

Country Status (20)

Country Link
US (4) US8129503B2 (fr)
EP (1) EP1948694B1 (fr)
JP (1) JP2009512672A (fr)
KR (1) KR20080066962A (fr)
CN (2) CN102302777A (fr)
AU (1) AU2006307733B2 (fr)
BR (1) BRPI0617771A2 (fr)
CA (1) CA2626939A1 (fr)
CR (1) CR9933A (fr)
EA (1) EA014106B1 (fr)
ES (1) ES2688941T3 (fr)
GB (1) GB0521621D0 (fr)
IL (1) IL190787A0 (fr)
MA (1) MA29882B1 (fr)
MX (1) MX2008005129A (fr)
NO (1) NO20081836L (fr)
NZ (1) NZ567441A (fr)
TW (1) TW200740848A (fr)
WO (1) WO2007049017A2 (fr)
ZA (1) ZA200803576B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
JP5308328B2 (ja) 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA2667466A1 (fr) * 2006-10-27 2008-05-02 Ablynx N.V. Administration intranasale de polypeptides et de proteines
ES2368764T3 (es) * 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688433A1 (fr) * 2007-06-06 2008-12-11 Domantis Limited Procede de selection de polypeptides resistant aux proteases
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
EP2195342A1 (fr) * 2007-09-07 2010-06-16 Ablynx N.V. Molécules de liaison présentant plusieurs sites de liaison, compositions comprenant de telles molécules et utilisations de celles-ci
EP2220115A2 (fr) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, domaines variables d'anticorps et antagonistes
WO2009089295A2 (fr) * 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps à domaine anti-vih et procédé de fabrication et d'utilisation de ceux-ci
WO2009127691A1 (fr) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant
EP2816113A3 (fr) * 2008-09-11 2015-03-25 Galapagos N.V. Procédés d'identification et composés utiles pour augmenter l'activité fonctionnelle et l'expression de surface cellulaire du régulateur de la conductance de trans-membrane de la fibrose kystique mutante associée à la mucoviscidose
KR20110091777A (ko) * 2008-11-26 2011-08-12 글락소 그룹 리미티드 폴리펩티드, 항체 가변 도메인 및 길항제
PT2387583T (pt) * 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
AU2010215479B2 (en) 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
WO2010144358A1 (fr) 2009-06-08 2010-12-16 Singulex, Inc. Groupes de biomarqueurs très sensibles
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2011006915A2 (fr) * 2009-07-16 2011-01-20 Glaxo Group Limited Domaines variables uniques de liaison anti-albumine sérique améliorés
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
AU2010310895A1 (en) * 2009-10-23 2012-05-03 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
JP2013507978A (ja) 2009-10-27 2013-03-07 グラクソ グループ リミテッド 安定な抗ｔｎｆｒ１ポリペプチド、抗体可変ドメイン及びアンタゴニスト
EP2531523A1 (fr) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capables de se lier à la sérumalbumine, et composés, constructions, et polypeptides comprenant de tels peptides
KR20190000385A (ko) * 2010-05-04 2019-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012022703A2 (fr) 2010-08-20 2012-02-23 Glaxo Group Limited Variants de liaison anti-sérum-albumine améliorés
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
WO2012072731A2 (fr) 2010-12-01 2012-06-07 Glaxo Group Limited Domaines variables améliorés à liaison unique d'anti-albumine sérique
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
AU2012205718B2 (en) 2011-01-10 2017-07-06 The Regents Of The University Of Michigan Stem cell factor inhibitor
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
HUE055348T2 (hu) 2012-11-20 2021-11-29 Opko Biologics Ltd Eljárás polipeptidek hidrodinamikus térfogatának növelésére gonadotropin karboxil-terminális peptidekhez való kapcsolással
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN103743909B (zh) * 2013-11-29 2015-11-25 漯河医学高等专科学校 弗林蛋白酶抑制剂对肺腺癌细胞生长和转移的影响研究方法
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US10561805B2 (en) 2014-10-10 2020-02-18 Ablynx N.V. Methods of treating RSV infections
EP3204095B8 (fr) 2014-10-10 2019-07-10 Ablynx N.V. Dispositif d'inhalation pour utilisation dans une thérapie par aérosol de maladies respiratoires
EP3230309B1 (fr) 2014-12-10 2023-03-29 OPKO Biologics Ltd. Procédés de production de polypeptides d'hormone de croissance modifiés par ctp à action prolongée
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CN109311968A (zh) 2016-05-02 2019-02-05 埃博灵克斯股份有限公司 治疗rsv感染
WO2018029474A2 (fr) 2016-08-09 2018-02-15 Kymab Limited Anticorps anti-icos
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
WO2018099968A1 (fr) 2016-11-29 2018-06-07 Ablynx N.V. Traitement d'une infection par le virus respiratoire syncytial (vrs)
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2018165619A1 (fr) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Anticorps de cd147, anticorps activables de cd147 et procédés associés de fabrication et d'utilisation
CN106756306B (zh) * 2017-03-10 2018-06-19 山东泰义金属科技有限公司 一种门窗用铝合金的加工方法
KR20180109272A (ko) 2017-03-27 2018-10-08 한양대학교 산학협력단 세포투과성 펩타이드와 ctCTLA4 펩타이드가 융합된 융합단백질을 유효성분으로 하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물
EP3710478A1 (fr) * 2017-11-13 2020-09-23 Crescendo Biologics Limited Molécules se liant à cd137 et psma
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019173771A1 (fr) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Anticorps activables de cd147 et procédés de fabrication et d'utilisation associés
US12448448B2 (en) 2018-06-20 2025-10-21 Incyte Corporation Anti-PD-1 antibodies and uses thereof
EP3927828A4 (fr) 2019-02-21 2023-02-01 Enosi Life Sciences Corp. Anticorps et énomomères
JP2022548310A (ja) 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
CN113261532A (zh) * 2020-02-17 2021-08-17 中山大学 一种肺癌动物模型的构建方法
KR20200033828A (ko) 2020-03-20 2020-03-30 한양대학교 산학협력단 세포투과성 펩타이드와 ctCTLA4 펩타이드가 융합된 융합단백질을 유효성분으로 하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물
CN113527488B (zh) 2020-04-22 2026-04-17 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CN111820188B (zh) * 2020-08-04 2021-10-29 中山大学附属第一医院 一种类哮喘慢阻肺重叠气道炎症小鼠模型的建立方法及其应用
CA3193273A1 (fr) 2020-08-27 2022-03-03 Enosi Therapeutics Corporation Methodes et compositions pour traiter des maladies auto-immunes et un cancer
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
KR102716104B1 (ko) 2021-07-09 2024-10-11 충남대학교산학협력단 폐 표적 25-하이드록시 콜레스테롤 나노하이브리드를 포함하는 covid-19 관련 사이토카인 폭풍 억제 조성물
WO2025049818A1 (fr) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Antagonistes tnfr1 dépourvus d'activité agoniste et leurs utilisations
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025259871A1 (fr) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anticorps anti-ccr8 et leurs utilisations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
CA2016842A1 (fr) 1989-05-16 1990-11-16 Richard A. Lerner Methode pour puiser dans le repertoire immunologique
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DK0626861T4 (da) * 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
AU2002219944B2 (en) * 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2005520854A (ja) * 2002-03-19 2005-07-14 アブジェニックス・インコーポレーテッド 慢性閉塞性肺疾患（ｃｏｐｄ）を治療するための方法
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
KR101317045B1 (ko) * 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
EP1578801A2 (fr) 2002-12-27 2005-09-28 Domantis Limited Anticorps a domaine unique ayant une double specificite pour un ligand et son recepteur
EP1617805A4 (fr) * 2003-04-11 2012-07-04 Medimmune Llc Procedes de prevention ou de traitement de conditions respiratoires
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra

Also Published As

Publication number Publication date
IL190787A0 (en) 2008-11-03
US9629909B2 (en) 2017-04-25
ES2688941T3 (es) 2018-11-07
WO2007049017A3 (fr) 2008-01-31
AU2006307733B2 (en) 2012-11-22
CN102302777A (zh) 2012-01-04
KR20080066962A (ko) 2008-07-17
US20120114651A1 (en) 2012-05-10
EP1948694A2 (fr) 2008-07-30
EA200800905A1 (ru) 2008-10-30
US8497244B2 (en) 2013-07-30
CN101346397B (zh) 2013-10-23
WO2007049017A2 (fr) 2007-05-03
CN101346397A (zh) 2009-01-14
US8129503B2 (en) 2012-03-06
JP2009512672A (ja) 2009-03-26
EP1948694B1 (fr) 2018-07-25
GB0521621D0 (en) 2005-11-30
TW200740848A (en) 2007-11-01
EA014106B1 (ru) 2010-10-29
CA2626939A1 (fr) 2007-05-03
AU2006307733A1 (en) 2007-05-03
US20170210814A1 (en) 2017-07-27
CR9933A (es) 2008-08-21
ZA200803576B (en) 2009-08-26
NO20081836L (no) 2008-06-23
MX2008005129A (es) 2008-10-23
NZ567441A (en) 2012-08-31
US20100034831A1 (en) 2010-02-11
US20130309227A1 (en) 2013-11-21
BRPI0617771A2 (pt) 2011-08-09

Similar Documents

Publication Publication Date Title
MA29882B1 (fr) Antagonistes du recepteur 1 du facteur de necrose des tumeurs servant a traiter des maladies respiratoires
Emerich et al. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation
JP4954085B2 (ja) 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
Fiellin et al. Opioid dependence: rationale for and efficacy of existing and new treatments
TW201105344A (en) Composition for the treatment of benign prostate hyperplasia
CN113164549A (zh) 包含针对Fas信号传导的抑制肽的用于预防或治疗肥胖症、脂肪肝或脂肪性肝炎的药物组合物
Miller et al. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.
Podkowa et al. The NMDA receptor antagonists memantine and ketamine as anti-migraine agents
Li et al. Metoprolol inhibits cardiac apoptosis and fibrosis in a canine model of chronic obstructive sleep apnea
TW202342050A (zh) 用於治療進行性纖維化間質性肺病之新穎治療組合
Hong et al. Moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin for target low-density lipoprotein cholesterol goal achievement in patients with recent ischemic stroke: a randomized controlled trial
Weisinger et al. Role of angiotensin in sodium appetite of sodium-deplete sheep
da Silva et al. Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives
Sehic et al. Complement reduction impairs the febrile response of guinea pigs to endotoxin
Opitz et al. Dual ETA/ETB vs. selective ETA endothelin receptor antagonism in patients with pulmonary hypertension
Jakubowska et al. Gepants: targeting the CGRP pathway for migraine relief
IL265099B2 (en) Pharmaceutical compositions comprising an effective amount of calcitonin gene-related peptide (cgrp) receptor antagonist or pharmaceutically acceptable salt thereof, for treating glaucoma
TW202339731A (zh) 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法
Edye et al. Epilepsy and the inflammasome: targeting inflammation as a novel therapeutic strategy for seizure disorders
Theodore et al. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration
Manakil et al. Oral health and nicotine replacement therapy product
TW202423403A (zh) 一種治療前列腺癌的藥物組合及其應用
Min et al. Positive feedback role of TRPC3 in TNF-α-mediated vasogenic edema formation induced by status epilepticus independent of ETB receptor activation
JP3916563B2 (ja) Ｐ物質の投与を含む治療方法